Your browser doesn't support javascript.
Protection From COVID-19 mRNA Vaccination and Prior SARS-CoV-2 Infection Against COVID-19-Associated Encounters in Adults During Delta and Omicron Predominance.
Bozio, Catherine H; Butterfield, Kristen A; Briggs Hagen, Melissa; Grannis, Shaun; Drawz, Paul; Hartmann, Emily; Ong, Toan C; Fireman, Bruce; Natarajan, Karthik; Dascomb, Kristin; Gaglani, Manjusha; DeSilva, Malini B; Yang, Duck-Hye; Midgley, Claire M; Dixon, Brian E; Naleway, Allison L; Grisel, Nancy; Liao, I Chia; Reese, Sarah E; Fadel, William F; Irving, Stephanie A; Lewis, Ned; Arndorfer, Julie; Murthy, Kempapura; Riddles, John; Valvi, Nimish R; Mamawala, Mufaddal; Embi, Peter J; Thompson, Mark G; Stenehjem, Edward.
  • Bozio CH; COVID-19 Emergency Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Butterfield KA; Westat, Rockville, Maryland, USA.
  • Briggs Hagen M; COVID-19 Emergency Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Grannis S; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.
  • Drawz P; School of Medicine, Indiana University, Indianapolis, Indiana, USA.
  • Hartmann E; Division of Nephrology and Hypertension, University of Minnesota, Minneapolis, Minnesota, USA.
  • Ong TC; Paso Del Norte Health Information Exchange, El Paso, Texas, USA.
  • Fireman B; School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
  • Natarajan K; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California, USA.
  • Dascomb K; Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.
  • Gaglani M; New York Presbyterian Hospital, New York, New York, USA.
  • DeSilva MB; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, USA.
  • Yang DH; Department of Pediatrics, Section of Pediatric Infectious Diseases, Baylor Scott and White Health, Temple, Texas, USA.
  • Midgley CM; Department of Medical Education, Texas A&M University College of Medicine, Temple, Texas, USA.
  • Dixon BE; HealthPartners Institute, Minneapolis, Minnesota, USA.
  • Naleway AL; Westat, Rockville, Maryland, USA.
  • Grisel N; COVID-19 Emergency Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Liao IC; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.
  • Reese SE; Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana, USA.
  • Fadel WF; Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon, USA.
  • Irving SA; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, USA.
  • Lewis N; Department of Pediatrics, Section of Pediatric Infectious Diseases, Baylor Scott and White Health, Temple, Texas, USA.
  • Arndorfer J; Westat, Rockville, Maryland, USA.
  • Murthy K; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.
  • Riddles J; Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana, USA.
  • Valvi NR; Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon, USA.
  • Mamawala M; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California, USA.
  • Embi PJ; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, USA.
  • Thompson MG; Department of Pediatrics, Section of Pediatric Infectious Diseases, Baylor Scott and White Health, Temple, Texas, USA.
  • Stenehjem E; Westat, Rockville, Maryland, USA.
J Infect Dis ; 227(12): 1348-1363, 2023 06 15.
Article in English | MEDLINE | ID: covidwho-2252865
ABSTRACT

BACKGROUND:

Data assessing protection conferred from COVID-19 mRNA vaccination and/or prior SARS-CoV-2 infection during Delta and Omicron predominance periods in the United States are limited.

METHODS:

This cohort study included persons ≥18 years who had ≥1 health care encounter across 4 health systems and had been tested for SARS-CoV-2 before 26 August 2021. COVID-19 mRNA vaccination and prior SARS-CoV-2 infection defined the exposure. Cox regression estimated hazard ratios (HRs) for the Delta and Omicron periods; protection was calculated as (1-HR)×100%.

RESULTS:

Compared to unvaccinated and previously uninfected persons, during Delta predominance, protection against COVID-19-associated hospitalizations was high for those 2- or 3-dose vaccinated and previously infected, 3-dose vaccinated alone, and prior infection alone (range, 91%-97%, with overlapping 95% confidence intervals [CIs]); during Omicron predominance, estimates were lower (range, 77%-90%). Protection against COVID-19-associated emergency department/urgent care (ED/UC) encounters during Delta predominance was high for those exposure groups (range, 86%-93%); during Omicron predominance, protection remained high for those 3-dose vaccinated with or without a prior infection (76%; 95% CI = 67%-83% and 71%; 95% CI = 67%-73%, respectively).

CONCLUSIONS:

COVID-19 mRNA vaccination and/or prior SARS-CoV-2 infection provided protection against COVID-19-associated hospitalizations and ED/UC encounters regardless of variant. Staying up-to-date with COVID-19 vaccination still provides protection against severe COVID-19 disease, regardless of prior infection.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Adult / Humans Language: English Journal: J Infect Dis Year: 2023 Document Type: Article Affiliation country: Infdis

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Adult / Humans Language: English Journal: J Infect Dis Year: 2023 Document Type: Article Affiliation country: Infdis